International Biotechnol... Share Discussion Threads

[maxwellsdemon] 17/8/2003 00:19

Discount to net asset value. From www.Trustnet.com

[mart] 17/8/2003 00:00

NAV now 106p.

[rambutan2] 24/7/2003 11:23

mr barker at it again...

All relevant boxes should be completed in block capital letters.

1. Name of company 2. Name of director
International Biotechnology Trust plc Andrew Barker

3. Please state whether notification indicates that it 4. Name of registered holder(s) and, if more than one
is in respect of holding of the director named in 2 holder, the number of shares held by each of them
above or holding of that person's spouse or children (if notified)
under the age of 18 or in respect of a
non-beneficial interest


Director Rock Nominees Limited

5. Please state whether notification relates to a 6. Please state the nature of the transaction. For PEP
person(s) connected with the director named in 2 transactions please indicate whether general/single
above and identify the connected person(s) co PEP and if discretionary/non discretionary
N/A Market Purchase

7. Number of shares/amount 8. Percentage of issued 9. Number of shares/ 10. Percentage of issued
of stock acquired class amount of stock class
disposed
25,000 0.052% - -

11. Class of security 12. Price per share 13. Date of transaction 14. Date company informed
Ordinary Shares 82.00p 24 July 2003 24 July 2003

15. Total holding following this notification 16. Total percentage holding of issued class following
this notification
95,000 Ordinary Shares 0.20%

[21up] 18/7/2003 00:35

Any guesses to the nav this week?

[mitzis] 17/7/2003 15:23

latest Nav is 110p acc to rns...

[rambutan2] 15/7/2003 17:00

good news for anormed yesterday.

[21up] 15/7/2003 16:36

Do we have lift off?

[rambutan2] 09/7/2003 19:46

in line with nas bio pretty much. this needs the ipo mkts to reopen and then it can really fly. but in the meantime it can still do very nicely, and dont forget that eyetech is due to come out with its trial results in the third quarter. (look back through the post for more details)

[21up] 09/7/2003 17:29

I see the nav is rising-any comments?

[rambutan2] 18/6/2003 16:25

novus is one of ours...

Cell Therapeutics (CTIC : NASDAQ : US$12.46)
Net Change: -2.29, % Change: -15.53%, Volume: 4,260,500
It was a busy day for this biotech... Following Monday's run up to $14.80 on
news of the FDA speeding their review of Cell's experimental treatment for
severe lung cancer, shares sold off sharply on news of plans to acquire
Italian biotech company Novuspharma in an effort to strengthen its
position as a provider of cancer-fighting drugs. Who will cover the bill,
you ask? After the close, Cell announced celling, er...selling, about $100
million of convertible senior notes due 2010 in a private placement. In
after-hours, shares traded as low as $11.49 on that final tidbit.

[janemary] 14/6/2003 12:01

rambutan2,
Many thanks for the info, currently researching main quoted investments with
the view to increase my holding from a very nominal level.

I agree the potential float of Aspen should be good news for WUN.

Be lucky and regards
Janemary

[rambutan2] 13/6/2003 12:23

hi janemary, have just had to come out of wun due to other considerations, but are watching v carefully and will get back in soon. the aspen stake could bring good news in the next few months.
here's what you need...


regards
rambutan

[janemary] 12/6/2003 23:07

Rambutan2,

Can you please advise me where I can find details of the current investments
held by IBT, is there a web site with these details ?

Are you still in WUN, very little movement in the recent past !

Regards Janemary.

[21up] 12/6/2003 14:42

N.A.V. up again this week i see.

[matt1231] 10/6/2003 12:21

Excellent news.Recent director buys point the way forward.

Interim report includes Micromet and Novuspharma announcing an alliance to co-develop an anti-cancer antibody and Sunesis and merck & Co announced a drug discovery collaboration in the area of Alzheimers disease.

Good management,good company.Happy with "The investment objective of the Company is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are publicly listed or approaching flotation or trade sale. IBT invests in companies that are under-valued ,with experienced management and strong potential upside through commercialisation of a product, device or enabling technology"

Given time can quitee see share price doubling and doubling again.IMHO,DYOR.

[rambutan2] 10/6/2003 00:32

another of ours with good news...

MedImmune and Micromet Sign Agreement to Co-develop Treatment for B Cell Tumors 
 
Partners also agree to create up to six new product opportunities based upon Micromet's novel platform of antibody derivatives 
 
Gaithersburg, MD, and Munich, Germany, June 9, 2003 –– MedImmune, Inc. (Nasdaq: MEDI) and Micromet AG (private) today announced an agreement to jointly develop Micromet's B cell tumor drug, MT103, the most-advanced representative of a novel class of antibody derivatives called Bi-Specific T Cell Engagers (BiTETM). In addition, the parties agreed to create up to six novel drug candidates using Micromet's proprietary BiTE product platform.

"This agreement with Micromet on MT103 and the promising BiTE platform reflects MedImmune's dedication to expanding its oncology pipeline," said James F. Young, Ph.D., MedImmune's president, research and development. "We are excited with the possibility of developing MT103 into a new treatment option for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. MT103 may also have application in autoimmune diseases, such as rheumatoid arthritis, myasthenia gravis, and systemic lupus erythematosus. We also look forward to working with Micromet to create additional drug candidates using the BiTE technology."

Micromet has initiated two European Phase 1 studies of MT103 in non-Hodgkin's lymphoma (NHL) and plans to initiate a Phase 1 study in chronic lymphocytic leukemia (CLL) later this year. The BiTE compound MT103 directs and activates the patients' own T cells (a very potent type of killer cell) against tumor cells. MT103 targets a particular protein (the CD19 antigen), which is present on the large majority of B cells (white blood cells) but not on other types of blood cells or healthy tissues. MT103 may therefore be applied to the treatment of all B-cell-related leukemias and lymphomas. The Leukemia & Lymphoma Society had estimated that approximately 53,900 Americans would be diagnosed with NHL in 2002, with approximately 7,000 new cases of CLL each year.

Under the terms of the agreement, Micromet will receive milestone payments based on the successful development, filing, registration and marketing of MT103, as well as royalties on MedImmune's North American sales of the product. Furthermore, MedImmune Ventures, Inc., a wholly owned venture capital subsidiary of MedImmune, will make an investment in Micromet. MedImmune receives Micromet's product rights to MT103 in North America and will assume responsibility for clinical development, registration and commercialization of the product in that region. As part of the agreement, MedImmune will develop the commercial manufacturing process and supply clinical trial material as well as commercial products for all markets. Micromet retains rights to MT103 outside of North America.

In addition to the MT103 co-development agreement, the parties will collaborate to create and develop up to six new products based on the BiTE platform. Micromet is entitled to receive milestones and royalties on future product sales of all resulting BiTE products. In addition, Micromet has the option to obtain exclusive European rights for BiTE compounds based on targets non-proprietary to MedImmune and the option to receive co-promotion rights in Europe for BiTE compounds based on MedImmune's proprietary targets. For each new BiTE molecule MedImmune will cover full development costs up to Phase 1. Micromet will be responsible for the generation of the new BiTE molecules. The parties expect to initiate the first joint BiTE program within the next six months.

Erich Felber, MD, chief executive officer of Micromet said, "We are pleased to establish a co-development relationship with MedImmune, one of the world's leading biotechnology companies. MedImmune's track record in building product franchises and its commitment to the oncology and antibody arena make them an ideal partner. The partnership not only strengthens our clinical-stage portfolio, but also creates and funds additional opportunities with the BiTE product platform." [End]

[matt1231] 07/6/2003 00:07

IBT, paused,consolidated and breaking out.Has 100p+ written all over it.IMHO.

[matt1231] 06/6/2003 14:52

rambutan2,thanks for sharing your research.One which caught my was Eyetech Pharmaceuticals as posted at 22.Only have to look back to 1999-2000 to see where IBT is going.Hidden gem.IMHO.

[rambutan2] 06/6/2003 14:20

yes, someone got wind of something? or just reeling in the discount? as always i checked out eyetech but this the most recent on their site, although still good stuff...

EYETECH PHARMACEUTICALS ENTERS DEAL FOR XALATAN, WORLD'S TOP-SELLING OPHTHALMIC MEDICATION
Eyetech Pharmaceuticals, Inc., Tuesday, April 22, 2003

NEW YORK, NY, April 22, 2003 - Eyetech Pharmaceuticals, Inc. today announced it has entered into an agreement with Pfizer Inc. in which Eyetech's sales force will participate in selling XALATAN(R) (latanoprost ophthalmic solution), Pfizer's once-daily prescription eye drop, to ophthalmologists and retinal specialists in the United States. XALATAN is the world's top-selling glaucoma medication and the first and only prostaglandin with a first-line indication for the treatment of elevated eye pressure (intraocular pressure or IOP) in the U.S. and Europe. Further terms of the deal were not disclosed.

"This agreement is particularly significant for Eyetech because it will allow us to accelerate building a top-notch, specialty field force organization in advance of potential commercialization of our lead product, Macugen (pegaptanib sodium)" said Dr. David Guyer, Eyetech Pharmaceuticals' co-founder and chief executive officer.

Previously, in December 2002 Pfizer and Eyetech announced a collaboration to jointly develop and commercialize Eyetech's Macugen(TM) (pegaptanib sodium), a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME), both leading causes of blindness. The two companies are currently supporting the largest Phase III development program for wet AMD, involving nearly 1,200 patients at 117 investigational sites in the United States, Canada, South America, Europe, Israel and Australia.

[mart] 06/6/2003 13:03

Hhmm, as somebody once said.

[rambutan2] 04/6/2003 19:29

this very worth noting as makes svls, led by our kate bingham, such a bio power. means ibt will have access to the best deals on offer and on same terms.
also piece on inside front page of ft business today...

Boston- and London-based life sciences sector Schroder Ventures Life Sciences announced today it closed its third fund on $402m.
The firm's second fund closed on $310m in 1999, according to a press release.
The firm's third fund attracted 18 new investors, with half of the commitments coming from North America and half coming from the U.K. and Europe.
The fund will focus on providing start-up, early stage, and expansion capital to life science companies in the U.S. and Europe. The firm focuses on companies in the biotechnology, pharmaceutical, medical devices, healthcare information technology and healthcare services industries. The typical investment size for the fund will be between $5m and $20m.
"This is a strong result in a difficult fund raising environment," James Garvey, chief executive officer and managing partner of Schroder Ventures life Sciences, said in the statement. "We set out deliberately to broaden our investor base and are delighted to welcome a significant number of new investors."
In March, Schroder Ventures Life Sciences participated in a €30 m ($32m) Series C round of financing in German drug discovery company Cellzome, a startup that uses functional proteomics technology for target discovery, validation, and drug development.
Schroder Ventures Life Sciences was founded in 1993. The firm has 23 investment professionals in Boston, London and San Francisco. The firm also advises the International Biotechnology Trust, a publicly quoted investment trust on the London Stock Exchange with a net asset value of $70m. IBT invests in life sciences companies with an emphasis on U.S. biotechnology companies.

[rambutan2] 04/6/2003 19:15

heres the seller...

Substantial Share Interest Notification

We are writing to advise that the Company was notified on 4 June 2003 that,
following a sale of 570,000 ordinary shares on 3 June 2003, East Riding of
Yorkshire Council no longer has a notifiable interest in the Company's issued
share capital.

[ranoszek] 03/6/2003 16:54

perhaps another purchase for cancellation?

[matt1231] 03/6/2003 16:13

Nice 'X' trade at mid price 570K at 75p.Things happening behind the scenes.All points north imho.